Introduction {#section1-1534735420924832}
============

The past years have witnessed rapid growth in the treatment of non--small cell lung cancer owing to targeted drugs. One class of agents includes the epidermal growth factor receptor inhibitors (EGFRIs), which have been shown to be efficacious in patients whose tumors harbor EGFR-activating mutations. Dermatologic toxicities are the most common side effects associated with the EGFRIs, in which xerosis commonly complicated by pruritus severely affects the quality of life.^[@bibr1-1534735420924832]^

Xerosis is a problem in up to 33% of patients treated with EGFRIs with pruritus and pain. The patients suffer from xerosis after taking EGFRIs for approximately 30 to 60 days. This condition is usually followed or accompanied by acneiform eruption. The typical appearances present dry, scaly, and itchy skin on any part of body. Some patients report vaginal and perineal dryness. Patients with xerosis may develop chronic asteatotic eczema that predisposes to secondary infections with *Staphylococcus aureus* or the herpes simplex virus.

The MASCC (Multinational Association of Supportive Care in Cancer) has recommended treatments for xerosis. The management mainly emphasizes prevention and external moisturizers, while the efficacy is far from satisfactory. Our goal as oncologists is to provide optimal patient care and improve quality of life with traditional Chinese medicine (TCM). It is expected that the implementation of such strategies will contribute to the optimization of EGFRIs therapies.

Methods {#section2-1534735420924832}
=======

Design {#section3-1534735420924832}
------

This study was a double-blinded, randomized, placebo-controlled trial. The study was to observe the curative effect of Zizao Yangrong granules in the treatment of EGFRIs-related xerosis and evaluate the prescription's safety. The patients were enrolled from China-Japan Friendship Hospital.

Ethical Approval {#section4-1534735420924832}
----------------

The trial was performed with the approval of the Ethics Committee of China-Japan Friendship Hospital for Drug/Instrument Clinical Researches (2016-23). All patients signed an informed consent form before randomization and treatment.

Participants {#section5-1534735420924832}
------------

A total of 68 patients were enrolled ([Figure 1](#fig1-1534735420924832){ref-type="fig"}), which were randomized to receive Zizao Yangrong granules or placebo in an allocation ratio of 1:1.

![Flow diagram of enrollment.](10.1177_1534735420924832-fig1){#fig1-1534735420924832}

Eligible patients had to meet the following inclusion criteria: (*a*) patients with malignant tumor confirmed by pathology or cytology; (*b*) patients with application of EGFRIs; (*c*) patients with EGFRIs-related skin xerosis; (*d*) no severe dysfunction of heart, liver, or kidney; (*e*) age from 18 to 85 years; (*f*) normal language ability and no mental disorders; (*g*) patients understand and agree to receive the treatment, and sign informed consent form; and (*h*) TCM syndrome: the syndrome of yin deficiency and blood dryness. The main symptoms include dry skin, itching, rare rash, desquamation, fatigue, dry mouth, red tongue with little fur, thready rapid pulse, or deep thready pulse.

Exclusion criteria were the following: (*a*) patients with EGFRI discontinuation; (*b*) patients with xerosis who did not meet the yin deficiency and blood dryness syndrome; (*c*) patients with allergic constitution; and (*d*) patients with poor compliance.

Outcomes and Endpoints {#section6-1534735420924832}
----------------------

As for clinical outcomes, the primary endpoints were changes of xerosis and pruritus evaluated by MASCC^[@bibr2-1534735420924832]^ and NCI-CTCAE (National Cancer Institute-Common Termi-nology Criteria for Adverse Events)^[@bibr3-1534735420924832]^ grading systems, respectively, every 2 weeks. The symptoms of dry mouth, eyes, and nose accompanying dry skin were also summarized. The secondary endpoints were water content of skin and the quality of life evaluated by Dermatology Life Quality Index.^[@bibr4-1534735420924832]^ The water content of skin was evaluated by the Soft Plus skin tester (Callegari, Italian) from limbs. The blood routine, liver, and kidney function were observed as safety indicators. According to the EGFRI Dermatologic Toxicity Forum, in 2006,^[@bibr5-1534735420924832]^ complete response (CR) was defined as dermatologic toxicities disappearing without subjective symptoms, sign of superinfection, and impact on activities of daily life; partial response (PR) was defined as the grade of dermatologic toxicities was lowered not \<1 level; no response (NR) was defined as the grade of dermatologic toxicities had no changes or proceeded to the higher grades. Response included CR and PR.

Intervention {#section7-1534735420924832}
------------

Patients in treatment group received oral Zizao Yangrong granules and control group received placebo granules. Both groups treated with external vitamin E ointment and were observed. The Zizao Yangrong granules mainly consisted of 5 TCM herbals, Radix Radix angelicae sinensis (当归), Rehmanniae Preparata (熟地黄), Scutellaria baicalensis Georgi (黄芩), Gentiana macrophylla Pall (秦艽), and Divaricate Saposhnikovia Root (防风), whose proportion was 3:3:3:2:2. The raw materials of the prescription in proportion are added to water and refluxed to extract twice, each time for 1.5 hours. The decoctions are combined, then filtered, concentrated, and 60% ethanol solution added to precipitate. The solution is allowed to stand, filtered, concentrated, and dried under reduced pressure. Dextrin was used as an excipient to make granules with the ratio of 3:1 between herbs and dextrin. The placebo was made of dextrin, starch syrup as adhesive, caramel pigment as colorant, and bitterant and aspartame as corrigent. They were packed with standardized packaging the same as Zizao Yangrong granules. The Zizao Yangrong granules or placebo were taken after dissolving in warm water twice a day for participants, while vitamin E ointment was applied externally. The intervention lasted 4 weeks.

Randomization and Blinding {#section8-1534735420924832}
--------------------------

The Zizao Yangrong granules and placebo granules were labeled with continuous codes, which represented randomization and intervention arms, and were pasted on the corresponding bags of granules. A form presented the code and the corresponding patients' randomization numbers. The randomization and codes were kept by an independent person blinded to the patients and researchers. The third party conducted coding and sealed blind codes. Researchers delivered drugs according to the corresponding form. The blind codes were uncovered twice. After verifying the blind situation, the research data were locked, and statisticians uncovered blind codes for the first time. The randomization was represented by A and B for statistical analysis. After the statistical analysis was over, the randomized group of A and B was published for the second time. If serious adverse events occurred, the emergency of breaking the blind was conducted; the responsible researchers decided whether to open the emergency letter. Once the emergency letter was opened, the case was considered as a case of shedding, not included in the efficacy analysis, but included in adverse reactions analysis.

Sample Size Calculations {#section9-1534735420924832}
------------------------

The sample size calculations were based on our previous observation. It was considered that the effective rate of Zizao Yangrong granules was 70%, and that of placebo was 35%. For 90% power with α set at 0.05, we calculated that 31 participants would be needed in both groups by 1-tailed test. Considering 10% as the noncompletion rate, each group needed 34 participants.

Statistical Analysis {#section10-1534735420924832}
--------------------

Statistical analyses were done using SPSS software version 20.0 and performed using 2-sided test. The statistical analysis of the differences for each experimental and control group was carried out using the Student's *t* tests for continuous variables with χ^2^ for the comparison of rate. *P* \< .05 were considered statistically significant.

Results {#section11-1534735420924832}
=======

The study started on May 12, 2016, and was completed on January 24, 2018. There were 70 patients eligible for screening. Because of discontinuing taking EGFRIs and meeting the exclusion criteria, 2 patients were excluded. A total of 68 patients were randomized and allocated. A patient discontinued intervention in the treatment group and a patient was lost to follow-up in the control group, so 66 out of 68 patients completed the study. The overall mean age of the patients was 68 (range = 38-85) years. A total of 23 (33.8%) male patients and 45 (66.2%) female patients were enrolled. The median of xerosis occurrence after taking target drugs was 90 days. The population distribution had no difference between the 2 groups ([Table 1](#table1-1534735420924832){ref-type="table"}).

###### 

Patients With EGFRIs-Related Dermatologic Toxicities in Treatment and Control Groups.

![](10.1177_1534735420924832-table1)

  Characteristics                                 Cases (n = 68)                 
  ----------------------------------------------- ---------------- ------------- ------
  Age (years), Mean ± SD                          68.9 ± 10.2      66.4 ± 11.1   .603
  Sex, n                                                                         .798
   Male                                           12               11            
   Female                                         22               23            
  Sites of xerosis, n                                                            .947
   Face and head                                  13               17            
   Neck                                           8                14            
   Breast                                         11               14            
   Back                                           16               23            
   Abdomen                                        12               16            
   Left upper limb                                23               29            
   Right upper limb                               24               29            
   Left lower limb                                34               32            
   Right lower limb                               33               33            
   Hip                                            14               12            
  The time to taking target drugs (day), median   90                             
  Xerosis grade                                                                  .851
   Grade 1A                                       0                0             
   Grade 1B                                       3                2             
   Grade 2A                                       4                6             
   Grade 2B                                       10               8             
   Grade 3A                                       14               13            
   Grade 3B                                       3                5             
  Pruritus                                                                       
   None                                           4                2             
   Grade 1                                        13               9             
   Grade 2                                        11               15            
   Grade 3                                        5                7             
  Responsible agent                                                              .651
   Icotinib                                       20               16            
   Gefitinib                                      9                12            
   Erlotinib                                      3                3             
   Osimertinib                                    1                2             
   Icotinib, osimertinib                          1                0             
   Gefitinib, osimertinib                         0                1             

Efficacy {#section12-1534735420924832}
--------

### Primary Endpoints {#section13-1534735420924832}

Of the 68 patients randomized to receive Zizao Yangrong granules and placebo combined with vitamin E ointment, 33 patients in each group were eligible for analysis. As for xerosis, the grade was significantly lowered after 2-week and 4-week treatment both in treatment group and control group based on statistical analysis (*P* \< .05). After the entire 4 weeks' treatment, 10 patients reported CR, and 18 patients reported PR with 5 patients NR in the treatment group, while 5 patients reported CR, and 20 patients reported PR with 8 patients NR in the control group. The overall curative effect of the treatment group (84.8%) was better than that of the control group (75.8%) in dry skin (*P* = .027; [Table 2](#table2-1534735420924832){ref-type="table"}).

###### 

Changes in Xerosis.

![](10.1177_1534735420924832-table2)

  Xerosis                 CR   PR   NR   RR (CR + PR)   *P*
  ----------------------- ---- ---- ---- -------------- ------
  Two weeks' treatment                                  
   Treatment              4    24   5    84.80%         .000
   Placebo                4    19   10   69.70%         
  Four weeks' treatment                                 
   Treatment              10   18   5    84.80%         .027
   Placebo                5    20   8    75.80%         

Abbreviations: CR, complete response; PR, partial response; NR, no response; RR, response rate.

In terms of pruritus, 29 patients in treatment group and 31 patients in control group suffered from this symptom. Fifteen patients reported CR, and 8 patients reported PR with 6 patients NR in treatment group, while 7 patients reported CR, and 12 patients reported PR with 12 patients NR in control group. The curative effect of the treatment group (79.3%) and control group (61.3%) was comparable (*P* = .269; [Table 3](#table3-1534735420924832){ref-type="table"}).

###### 

Changes in Pruritus.

![](10.1177_1534735420924832-table3)

  Pruritus                CR   PR   NR   RR (CR + PR)   *P*
  ----------------------- ---- ---- ---- -------------- ------
  Two weeks' treatment                                  
   Treatment              13   8    8    72.40%         ---
   Placebo                4    14   13   58.10%         .000
  Four weeks' treatment                                 
   Treatment              15   8    6    79.30%         ---
   Placebo                7    12   12   61.30%         .269

Abbreviations: CR, complete response; PR, partial response; NR, no response; RR, response rate.

In addition, most patients included have the symptoms of dry mouth, eyes, and nose, while the analysis of symptom changes showed no significant difference.

### Secondary Endpoints {#section14-1534735420924832}

After 2-week and 4-week treatment, the results of skin water content evaluation showed the water content of limbs increased (*P* \< .05) except for the left lower limb in treatment group, while the water content of limbs increased (*P* \< .05) except for the left lower limb in control group. No difference was observed in 2 groups after 2-week and 4-week treatment ([Table 4](#table4-1534735420924832){ref-type="table"}).

###### 

Comparison of Skin Water Content Between 2 Groups.

![](10.1177_1534735420924832-table4)

  Skin Water Content   Before Treatment   Two Weeks' Treatment   Four Weeks' Treatment
  -------------------- ------------------ ---------------------- -----------------------
  *P*                  .45                .793                   .504

The Dermatology Life Quality Index suggested that the quality of life significantly increased after 2-week and 4-week treatment both in treatment group and control group based on statistical analysis (*P* \< .05). Encouragingly, the quality of life in the treatment group was highly improved compared with the control group (*P* = .045; [Table 5](#table5-1534735420924832){ref-type="table"}).

###### 

Comparison of Dermatology Life Quality Index (DLQI) Score Between 2 Groups.

![](10.1177_1534735420924832-table5)

  DLQI Score   Before Treatment   Two Weeks' Treatment   Four weeks' Treatment
  ------------ ------------------ ---------------------- -----------------------
  *P*          .058               .016                   .045

Safety {#section15-1534735420924832}
------

The most common drug-related adverse events were mild gastrointestinal and respiratory symptoms, such as nausea, vomiting, abdominal pain, diarrhea, and cough. No fatal events were reported during the study. Four (12.1%) patients reported gastrointestinal symptoms and 2 (5.9%) patients reported respiratory symptoms in both the groups. In addition, 1 (3.0%) patient in the treatment group was observed to have abnormal liver function, which may have some relation to the targeted therapy. The adverse events could be well controlled with routine management. No important harm in either group were observed.

Discussion {#section16-1534735420924832}
==========

Xerosis, one of the common dermatological adverse events, occurred in 10% to 49% (moderate-and-severe grade 0% to 7%) patients with the use of EGFRIs.^[@bibr6-1534735420924832]^ For the review of large randomized controlled trials, erlotinib accounted for the highest incidence of xerosis, followed by gefitinib and afatinib, while xerosis was rarely reported with icotinib. Xerosis was not observed in cetuximab and panitumumab^[@bibr7-1534735420924832]^ ([Table 6](#table6-1534735420924832){ref-type="table"}). However, the patients enrolled in this study mostly took icotinib, since it was developed and approved in China and recommended to more Chinese as anti-EGFR therapy. The site of xerosis has lacked systematic observation. In our study, limbs, head, and face tended to more susceptible.

###### 

Incidence of EGFRIs Xerosis in RCTs.

![](10.1177_1534735420924832-table6)

  Lead Author                                    Study                Patients (n)   EGFRIs Treatment   Xerosis   
  ---------------------------------------------- -------------------- -------------- ------------------ --------- -----
  Crinò et al^[@bibr8-1534735420924832]^         INVITE               196            Gefitinib          6.4       0
  Kim et al^[@bibr9-1534735420924832]^           INTEREST             1466           Gefitinib          15.2      0
  Mok et al^[@bibr10-1534735420924832]^          IPASS                1217           Gefitinib          23.9      0
  Mitsudomi et al^[@bibr11-1534735420924832]^    WJTOG3405            177            Gefitinib          54        0
  Lee et al^[@bibr12-1534735420924832]^          ISTANA               161            Gefitinib          14.8      0
  Ciuleanu et al^[@bibr13-1534735420924832]^     TITAN                2590           Erlotinib          4         0
  Zhang et al^[@bibr14-1534735420924832]^        INFORM/C-TONG 0804   296            Gefitinib          6         0
  Ramalingam et al^[@bibr15-1534735420924832]^   A7471028             188            Dacomitinib        23.7      1.1
                                                                                     Erlotinib          14.9      2.1
  Sequist et al^[@bibr16-1534735420924832]^      LUX-Lung 3           1269           Afatinib           29.3      0.4
  Seto et al^[@bibr17-1534735420924832]^         JO25567              154            Erlotinib          75        3
  Price et al^[@bibr18-1534735420924832]^        ASPECCT              999            Panitumumab        25        0.4
                                                                                     Cetuximab          24        0.6
  Ellis et al^[@bibr19-1534735420924832]^        NCIC CTG BR.26       720            Dacomitinib        29        \<1
  Ramalingam et al^[@bibr20-1534735420924832]^   ARCHER 1009          878            Dacomitinib        19        \<1
                                                                                     Erlotinib          18        0
  Soria et al^[@bibr21-1534735420924832]^        LUX-Lung 8           795            Afatinib           9         \<1
                                                                                     Erlotinib          11        0
  Wu et al^[@bibr22-1534735420924832]^           ENSURE               217            Erlotinib          9.1       0
  Schuler et al^[@bibr23-1534735420924832]^      LUX-Lung 5           202            Afatinib           4.5       0
  Mok et al^[@bibr24-1534735420924832]^          AURA3                419            Osimertinib        23        0
  Wu et al^[@bibr25-1534735420924832]^           ARCHER 1050          452            Dacomitinib        27        1
                                                                                     Gefitinib          17        0
  Yang et al^[@bibr26-1534735420924832]^         CTONG 0901           256            Gefitinib          11        0
                                                                                     Erlotinib          13        0
  Paz-Ares et al^[@bibr27-1534735420924832]^     LUX-Lung 7           319            Afatinib           32.5      0
                                                                                     Gefitinib          37.1      0
  Scagliotti et al^[@bibr28-1534735420924832]^   MARQUEE              1048           Erlotinib          15.1      0
  Soria et al^[@bibr29-1534735420924832]^        FLAURA               556            Osimertinib        33        1
                                                                                     Gefitinib          33        3

Abbreviations: EGFRIs, epidermal growth factor receptor inhibitors; RCTs, randomized controlled trials.

The mechanism of xerosis is not well explained. It is possible that abnormal keratinocyte differentiation caused by EGFRIs can impair the epidermal barrier, decreasing loricrin, the main protein forming the scaffold for the epidermis. Ultimately, xerosis is caused by an unwoven epidermal layer that loses moisture.^[@bibr30-1534735420924832]^ Previous study showed that patients who are taking gefitinib experienced cutaneous side effects including xerosis cutis, acneiform eruptions, and paronychia, and had mean transepidermal water loss values higher than normal.^[@bibr31-1534735420924832]^ In our study, we evaluated the skin water content by the skin testing instrument to illustrate the efficacy of Zizao Yangrong granules.

Topical moisturizers are encouraged for patients suffering from EGFRIs-related skin xerosis; however, the most water retention in the skin and general xerosis is hard to improve. Until now, no systematic study designed to observe TCM for EGFRIs-related skin xerosis has been published. This Zizao Yangrong prescription seems to be more effective than moisturizer in treating xerosis. Although there was only narrow difference with efficiency, the general xerosis was obviously relieved. The quality of life was also improved. As for pruritus, the Zizao Yangrong granules and vitamin E ointment have comparable effect. This result may be affected by the limited number of cases. Twenty-nine cases with pruritus were in the treatment group and 31 cases in the control group. The skin water content may be influenced by the external environment in our observation.

Zizao Yangrong formula consisted of Danggui, Shudi, Huangqin, Qinjiao, and Fangfeng. In the theory of treatment based on syndrome differentiation of TCM, the Zizao Yangrong prescription has the function of nourishing yin and blood, moistening dryness, and eliminating itch. Danggui is the root of *Angelica sinensis*. Its main chemical compounds are neutral oil components such as β-pinene, α-pinene, and terpenes. Its acidic oil component contains compounds such as p-methylbenzyl alcohol or 5-methoxy-2,3-xylenol, an organic acid, a saccharide, a vitamin, an amino acid, and others. It has the functions of promoting blood circulation, anti-inflammatory, antitumor, and analgesia.^[@bibr32-1534735420924832]^ Shudi is the root of *Dioscorea zingiberensis*, containing emodin, mannitol, vitamin A, sugar, and amino acids. It has the functions of promoting hematopoiesis, anti-oxidation, antiaging, anti-fatigue, antitumor, and immune enhancement.^[@bibr33-1534735420924832]^ Huangqin is the dried root of *Astragalus membranaceus*, which contains baicalin, wogonin, baicalein, acetophenone, and β-sitosterol. It has anti-inflammatory activity related to its inhibition of NO, cytokine, chemokine, and growth factor production in macrophages.^[@bibr34-1534735420924832]^ Qinjiao is the dried root of *Gentiana macrophylla, Gentiana straminea*, or *Rhizoma chinensis*. It contains prostrate A, B, C, gentiopicrin, angelica, montanic acid, methyl montanate, α-romatic alcohol, β-sitosterol, and has the functions of anti-inflammatory, immunosuppressive, liver-protecting, antiviral, calming, and analgesic effects.^[@bibr35-1534735420924832]^ Fangfeng is the root of a plant in the Umbelliferae family, which contains volatile oil, mannitol, β-sitosterol, picric acid, phenols, polysaccharides, and organic acids. It has anti-inflammatory, anti-allergic, antipyretic and analgesic effects, and regulates immunity.^[@bibr36-1534735420924832]^

It is critical for oncologists and dermatologists to recognize target therapy--induced xerosis, understand its mechanisms and choose optimum treatments for patients. TCM may provide us a new treatment decision, improving therapy compliance, and the quality of life. This study was the first randomized, double-blind, placebo-controlled study of TCM for EGFRIs-related xerosis. Some limitations of the study provide implications for future studies. We collected the symptoms of dry mouth, eyes, and nose, for which the analysis of symptom changes showed no significant difference. In addition, the tongue and pulse were observed, but we failed to find obvious differences before and after TCM treatment ([Figure 2](#fig2-1534735420924832){ref-type="fig"}). We think these results may be related to the course of treatment, which may not have been long enough to change the patients' constitution. Further study will pay more attention to the changes of syndrome.

![The effect comparison of xerosis before and after using Zizao Yangrong granules in the treatment group.](10.1177_1534735420924832-fig2){#fig2-1534735420924832}

Conclusion {#section17-1534735420924832}
==========

Zizao Yangrong granules have a significant curative effect on EGFRIs-related skin xerosis and improve the quality of life without serious adverse reactions. Moreover, Chinese medicine has broad prospects in the treatment of targeted drugs--related dermatologic adverse reactions. A larger study is needed to verify this finding.
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